Xtandi 40 MG capsule 120S
Ended Awarded Last action
- Contract number
- SPE2DR26FFCA7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $44,222
Award facts
- Contract value 100% obligated
- $44,221.60 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $44,221.60 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120 count). This firm fixed-price delivery order, issued on February 4, 2026, with an ultimate completion date of February 5, 2026, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a comprehensive $30.3 billion acquisition strategy designed to establish regional prime vendor contractors for Department of Defense pharmaceutical supply needs worldwide.
DMS Pharmaceutical Group has established itself as a critical pharmaceutical supplier within the federal military medical supply chain, with its parent contract (SPE2DR) carrying a $499,999,999 ceiling and extending through December 31, 2036. The company's extensive product portfolio encompasses branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals, with demonstrated performance across numerous delivery orders issued by the Defense Logistics Agency's Medical Supply Chain division. As the sole prime contractor on this delivery order with no identified subcontractors, DMS Pharmaceutical Group continues to support recurring medical supply requirements for Department of Defense healthcare facilities through the PPV-G GEN V program structure.
Quick answers
Who was awarded contract SPE2DR26FFCA7?
SPE2DR26FFCA7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on February 4, 2026.
How much is contract SPE2DR26FFCA7 worth?
The government has obligated $44,222 on SPE2DR26FFCA7.
Is contract SPE2DR26FFCA7 an order under another contract?
Yes. SPE2DR26FFCA7 is a delivery order under SPE2DR25D9239, an indefinite delivery contract.
Was contract SPE2DR26FFCA7 competed?
The extent of competition for SPE2DR26FFCA7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award